Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

McMahon AW, Eidex RB, Marfin AA, Russell M, Sejvar JJ, Markoff L, Hayes EB, Chen RT, Ball R, Braun MM, Cetron M; Yellow Fever Working Group..

Vaccine. 2007 Feb 26;25(10):1727-34. Epub 2006 Nov 27.

PMID:
17240001
2.

Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):989-93.

3.

Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.

Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T.

Curr Drug Saf. 2011 Jul;6(3):145-54. Review.

PMID:
22122389
4.

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

Breugelmans JG, Lewis RF, Agbenu E, Veit O, Jackson D, Domingo C, Böthe M, Perea W, Niedrig M, Gessner BD, Yactayo S; YF AEFI group..

Vaccine. 2013 Apr 3;31(14):1819-29. doi: 10.1016/j.vaccine.2013.01.054. Epub 2013 Feb 7.

PMID:
23395587
5.

Adverse event reports following yellow fever vaccination.

Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB.

Vaccine. 2008 Nov 11;26(48):6077-82. doi: 10.1016/j.vaccine.2008.09.009. Epub 2008 Sep 20.

PMID:
18809449
6.

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS; Yellow Fever Vaccine Safety Working Group..

Vaccine. 2005 May 9;23(25):3256-63.

PMID:
15837230
7.

Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004.

Vellozzi C, Mitchell T, Miller E, Casey CG, Eidex RB, Hayes EB.

Am J Trop Med Hyg. 2006 Aug;75(2):333-6.

PMID:
16896144
8.

Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.

Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T.

Vaccine. 2011 Jun 20;29(28):4544-55. doi: 10.1016/j.vaccine.2011.04.055. Epub 2011 May 5. Review.

PMID:
21549787
9.

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.

Bae HG, Domingo C, Tenorio A, de Ory F, Muñoz J, Weber P, Teuwen DE, Niedrig M.

J Infect Dis. 2008 Jun 1;197(11):1577-84. doi: 10.1086/587844.

PMID:
18419548
10.

Viscerotropic disease following yellow fever vaccination in Peru.

Whittembury A, Ramirez G, Hernández H, Ropero AM, Waterman S, Ticona M, Brinton M, Uchuya J, Gershman M, Toledo W, Staples E, Campos C, Martínez M, Chang GJ, Cabezas C, Lanciotti R, Zaki S, Montgomery JM, Monath T, Hayes E.

Vaccine. 2009 Oct 9;27(43):5974-81. doi: 10.1016/j.vaccine.2009.07.082. Epub 2009 Aug 11.

PMID:
19679215
11.
12.

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

Doblas A, Domingo C, Bae HG, Bohórquez CL, de Ory F, Niedrig M, Mora D, Carrasco FJ, Tenorio A.

J Clin Virol. 2006 Jun;36(2):156-8. Epub 2006 Apr 4.

PMID:
16597510
13.

Longitudinal myelitis associated with yellow fever vaccination.

Chaves M, Riccio P, Patrucco L, Rojas JI, Cristiano E.

J Neurovirol. 2009 Jul;15(4):348-50. doi: 10.1080/13550280903062805. Erratum in: J Neurovirol. 2010 Aug;16(4):334.

PMID:
19579072
14.

Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2006 Oct 20;55(41):1120-4. Erratum in: MMWR Morb Mortal Wkly Rep. 2006 Nov 3;55(43):1177.

15.

[Yellow fever vaccination in non-immunocompetent patients].

Bruyand M, Receveur MC, Pistone T, Verdière CH, Thiebaut R, Malvy D.

Med Mal Infect. 2008 Oct;38(10):524-32. doi: 10.1016/j.medmal.2008.06.031. Review. French.

PMID:
18715730
16.

Adverse event reports following yellow fever vaccination, 2007-13.

Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE.

J Travel Med. 2016 Jul 4;23(5). pii: taw045. doi: 10.1093/jtm/taw045. Print 2016 May.

PMID:
27378369
17.

Yellow fever-associated viscerotropic disease in Barcelona, Spain.

Muñoz J, Vilella A, Domingo C, Nicolas JM, de Ory F, Corachan M, Tenorio A, Gascon J.

J Travel Med. 2008 May-Jun;15(3):202-5. doi: 10.1111/j.1708-8305.2008.00209.x. Review.

18.

Yellow fever vaccine-associated neurotropic disease (YEL-AND) - A case report.

Florczak-Wyspiańska J, Nawotczyńska E, Kozubski W.

Neurol Neurochir Pol. 2017 Jan - Feb;51(1):101-105. doi: 10.1016/j.pjnns.2016.09.002. Epub 2016 Sep 22.

PMID:
27707454
19.

[Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].

Yaméogo TM, Breugelmans JG, Kambou JL, Badolo O, Tiendrebéogo S, Traoré E, Avokey F, Yactayo S.

Med Trop (Mars). 2009 Aug;69(4):320-1. French.

PMID:
19725376
20.

Review of the risks and benefits of yellow fever vaccination including some new analyses.

Monath TP.

Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6. Review.

PMID:
22551029

Supplemental Content

Support Center